Vericel (FRA:ATQP) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:ATQP Vericel Corp FRA:ATQP
28 GF Score
Price €40.40
GF Value €46.49
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Vericel FFO per Share?

FFO per Share only applies to REITs.

FRA:ATQP
28GF Score
Vericel Corp FRA:ATQP
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €40.40 is trading 13.1% below its estimated GF Value™ of €46.49. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for FRA:ATQP:

  • FFO per Share:
  • GF Value™: €46.49 vs. price of €40.40 (13.1% below fair value)
  • GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
28GF Score

Get the complete analysis for FRA:ATQP

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€40.40
Price
€46.49
GF Value